InvestorsHub Logo
Followers 3
Posts 295
Boards Moderated 0
Alias Born 12/21/2022

Re: Tartiaboy post# 315

Wednesday, 03/29/2023 12:30:52 PM

Wednesday, March 29, 2023 12:30:52 PM

Post# of 572
ADMIRAL trial was Gilteritinib against salvage therapy in r/r AML patients with Flt3 mutations. Several salvage regimens are available. I guess, they can be used as a control arm in Tusp mono trial.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News